Lawmakers question Vytorin cancer risk data
WASHINGTON (Reuters) - Two top Democratic lawmakers on Thursday questioned recent claims by Merck & Co Inc and Schering Plough Corp that incidents of cancer in patients taking their cholesterol drug Vytorin were a fluke.
The lawmakers, Rep. John Dingell and Rep. Bart Stupak, both from Michigan, are seeking 10 years of related company records after a study last month found Vytorin patients had a higher rate of cancer than those taking a placebo.
(Reporting by Susan Heavey; editing by John Wallace)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Revenue Cycle Management/ Healthcare
Details: Growing Healthcare Consultancy organization...seeks experienced Healthcare Revenue Cycle Management...initiatives to healthcare providers and payers...
Work from Home as a Healthcare Recruiter
Details: ...from Home as a Healthcare Recruiter Health...an international healthcare recruiting and...represents high-demand healthcare professionals and...
Regional Operations Director - Healthcare
Details: ...Operations Director - Healthcare This position will...skills/experience: Healthcare Multi-Site Management...benefits including the healthcare industry's most...
Lawson Analyst - Payroll for healthcare
Details: ...experience within a healthcare industry environment...Application Analyst, Healthcare Systems, Payroll...Analyst - Payroll for healthcare position, and have...
Space beer lands in Japan
